This study identifies dolutegravir as a novel BRD9 inhibitor and demonstrates that BRD9 is a key regulator of high glucose-induced pyroptosis and pro-fibrotic signaling in mesothelial cells via modulation of NLRP3 mRNA stability. These findings suggest a new therapeutic strategy for preventing peritoneal fibrosis and highlight the potential of computational drug repurposing.
Gai et al. (Tue,) studied this question.